The global circulating tumor cell market size is expected to reach around USD 23.9 billion by 2027 at a CAGR of 13.2% over the forecast period, according to a new report by Grand View Research, Inc. The growth in cancer-related spending for the introduction of companion diagnostics and targeted therapies has driven the circulating tumor cell (CTC) market over the past years. Research organizations are engaged in endeavors aimed at developing circulating tumor cells based tests to improve cancer diagnosis in terms of efficiency and speed.
Furthermore,
the growing demand for minimally invasive diagnostic procedures is anticipated
to propel investments by key stakeholders in this area. Circulating tumor cell
based liquid biopsy tests lead to limited trauma and enable rapid recovery
owing to their non-invasive nature. Moreover, it enables minimal invasive
screening of tumors before opting for complex surgical procedures, such as
radiotherapy, chemotherapy, and surgical removal of tumors, thus positively
impacting the adoption.
The
limited applicability of these cells in rare cancers has hampered the revenue
growth up to a certain extent. For instance, there is a negligible evidence for
the characterization of circulating tumor cells for sarcoma. Conversely,
several methods are being investigated for isolation of these cells, such as
methods based on epithelial antigen-targeted antibodies, which are anticipated
to help overcome these challenges in the coming years.
Full Research Report On Circulating Tumor Cell Market Visit Here:
https://www.grandviewresearch.com/industry-analysis/circulating-tumor-cells-market
Circulating Tumor
Cell Market Report Highlights
- CTC detection and enrichment
methods accounted for the largest revenue share owing to the presence of
wide availability of products for CTC enrichment and isolation
- Moreover, high penetration
in terms of usage of products offered under this segment has driven the
segment share
- Growing application of
nanomaterials in cancer management is anticipated to drive revenue for
direct detection methods in the coming years
- Devices and systems
dominated the revenue share in 2019 over its counterpart segments
including kits and reagents and blood collection tubes
- Presence of high-throughput
automated systems coupled with the availability of a substantial number of
systems to carry out detection of tumor cells has contributed to large
revenue share
- CTC analysis has major
applications in research settings, including investigational research,
drug developments, and biomarker studies. This has resulted in a segment’s
large revenue share
- Currently, whole blood
specimens are the key source of CTCs, thus accounting for the largest
share in 2019
- Low use of bone
marrow-derived cells in clinical settings has contributed to a smaller
revenue share of this segment
- Other sources include CSF,
spinal fluids, urine, and pleural effusion
- Easy availability of
biological specimens, such as urine, is likely to accelerate adoption
under this segment
- The CTC market is fragmented
in nature with the presence of well-established players, along with medium
to small-sized players
- Some players operating in
the space are QIAGEN; Greiner Bio One International GmbH; Menarini Silicon
Biosystems; Sysmex Corporation; Bio-Techne Corporation; and Biocept, Inc.
Request a Sample Copy of the Report @
https://www.grandviewresearch.com/industry-analysis/circulating-tumor-cells-market/request/rs1
Circulating Tumor
Cell Market Segmentation
Grand View Research has segmented
the global circulating tumor cell market on the basis of technology,
application, product, specimen, and region:
CTC Technology
Outlook (Revenue, USD Million, 2016 - 2027)
- CTC Detection &
Enrichment Methods
- Immunocapture (Label-based)
- Positive Selection
- Negative Selection
- Size-based Separation
(Label-free)
- Membrane-based
- Microfluidic-based
- Density-based Separation (Label-free)
- Combined Methods
- CTC Direct Detection Methods
- SERS
- Microscopy
- Others
- CTC Analysis
CTC Application
Outlook (Revenue, USD Million, 2016 - 2027)
- Clinical/Liquid Biopsy
- Risk Assessment
- Screening and Monitoring
- Research
- Cancer Stem Cell &
Tumorigenesis Research
- Drug/Therapy
Development
CTC Product Outlook
(Revenue, USD Million, 2016 - 2027)
- Kits & Reagents
- Blood Collection Tubes
- Devices or Systems
CTC Specimen
Outlook (Revenue, USD Million, 2016 - 2027)
- Blood
- Bone Marrow
- Other Body Fluids
CTC Regional
Outlook (Revenue, USD Million, 2016 - 2027)
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Australia
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- UAE
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment